Odyssey Therapeutics Reports Q1 2026 Results, Confirms Strong Liquidity Post-IPO, Extending Cash Runway into H2 2028
ODTX sits 16% above its 52-week low of $16.
Summary
Odyssey Therapeutics reported Q1 2026 results, highlighting a strong cash position and extended runway into H2 2028 following its recent IPO and private placement, which raised $288.7 million.
Key Events · Financing and Capital Events · ODTX
-
Successful IPO and Private Placement
The company completed its initial public offering (IPO) and a concurrent private placement in May and June 2026, raising aggregate net proceeds of $288.7 million. This includes 15.5 million shares sold in the IPO at $18.00 per share, a $23.3 million private placement, and an additional $10.0 million from underwriters' option exercise.
-
Extended Cash Runway
With existing cash, cash equivalents, and marketable securities of $175.7 million as of March 31, 2026, combined with the IPO proceeds, the company expects to fund operations into the second half of 2028, resolving prior going concern conditions.
-
Q1 2026 Financial Performance
Odyssey Therapeutics reported a net loss of $38.3 million for the three months ended March 31, 2026, compared to $38.4 million for the same period in 2025. Collaboration revenue decreased to zero as prior agreements concluded.
-
Reverse Stock Split Effected
On May 1, 2026, the company effected a 1-for-9.7170 reverse stock split, retroactively adjusting all share and per-share information in the financial statements.
Analysis · ODTX · Life Sciences
This quarterly report provides the financial backdrop to Odyssey Therapeutics' recent public listing and ongoing clinical development. The company successfully completed its IPO and a concurrent private placement in May and June 2026, raising significant net proceeds of $288.7 million. This capital infusion has resolved prior going concern doubts and is expected to fund operations into the second half of 2028, providing crucial runway for its clinical-stage pipeline, including the lead candidate OD-001 which recently reported positive proof-of-concept data. While the company continues to incur net losses, this substantial capital raise is a critical positive for a clinical-stage biopharmaceutical company.
At the time of this filing, ODTX was trading at $18.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $871.8M. The 52-week trading range was $16.00 to $18.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.